LY
Lyka Labs Limited
LYKALABS.BO · BSE
₹72.50 -3.37% (-₹2.53)
1M -7.94%
Market Cap ₹2.68B
P/E Ratio -
Div. Yield -
ROE 8.93%
Bulios Fair Price
₹38.39
47.0% downside
Current Price
₹72.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LYKALABS.BO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
34 /100
Fair P/S 1.94x
P/B 2.90x
P/FCF 52.04x
Growth
81 /100
Growing Rev. growth 11.89%
Book val. growth 26.69%
EPS growth N/A
Profitability
16 /100
Weak Gross margin 22.63%
Net margin 6.46%
Op. margin 8.10%
Quality
10 /100
Poor ROIC 6.39%
ROE 8.93%
ROA 5.10%
Debt
48 /100
Moderate Debt/Equity 0.53x
Current ratio 1.17x
Int. coverage -2.68x
Stability
16 /100
Unstable Beta 0.16x
Rev. volatility 21.33%
EPS volatility 312.45%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LYKALABS.BO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Kunal Narendra Gandhi
Employees
648
Headquarters
Mumbai